MedTrace Logo

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

NCT04510493 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2021-09-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether Canakinumab has beneficial effects on patients with Type 2 diabetes mellitus and coronavirus disease 19 (COVID19).

Conditions

  • Coronavirus Infection
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Canakinumab

Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours

DRUG

Placebo

Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Swiss National Science Foundation

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Marc Donath, MD, Prof. · University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2021-08-17
Completion
2021-08-17

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510493 on ClinicalTrials.gov